JPRN-jRCT2080222525未知2 期
A Phase II, double-blind, parallel-group comparison study of S-556971 in patients with dyslipidemia
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Patients with dyslipidemia classified into category I and category II for primary prevention defined by Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
排除标准
- •Patients with secondary dyslipidemia.
- •Patients with severe hepatic, renal, cardiac, respiratory, or blood disorders.
研究者
相似试验
招募中
2 期
A phase II Clinical trial of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active ulcerative colitisCTRI/2022/11/047054Biocon Limited
未知
2 期
A Phase 2 Randomised, Double-Blind, Parallel Group, 4-Week Treatment, Adaptive Dose Finding, Multi-Centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the KneeJPRN-jRCT2080220732AstraZeneca
已完成
2 期
A phase II/III clinical study to evaluate the immunogenicity and safety of three formulations of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults.CTRI/2010/091/000032Panacea Biotec Limited360
进行中（未招募）
1 期
Dose-finding study of moxidectin for the treatment of scabiesScabies (infection with Sarcoptes scabiei)MedDRA version: 20.1Level: LLTClassification code 10039511Term: ScabiesSystem Organ Class: 100000004862EUCTR2019-001775-37-FRMedicines Development Limited (trading as Medicines Development for Global Health)18
进行中（未招募）
1 期
A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or placebo in postmenopausal women with osteoporosis.OsteoporosisEUCTR2006-000635-94-GBGlaxoSmithKline Research & Development